LEGN Legend Biotech USA Inc.
Price Chart
Executive Summary
Legend Biotech announced multiple ASCO 2026 presentations, including a rapid oral presentation of preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in SCLC/LCNEC) and new CARTITUDE-4 subgroup analyses. The LB2102 data show a manageable safety profile and early clinical activity in solid tumors, extending CAR-T beyond hematologic malignancies. CARVYKTI continues to expand commercially (18 countries, 10,000+ patients treated).
Actionable Insight
The LB2102 rapid oral presentation at ASCO is a positive catalyst for Legend's solid tumor pipeline, but Phase 1 data are preliminary. Monitor the ASCO presentation (May 31) for response rates and durability. CARVYKTI's commercial momentum (18 countries, 10K+ patients) supports revenue growth but is already priced in. The Novartis partnership de-risks LB2102 development. Near-term volatility likely around ASCO data release.
Key Facts
- Phase 1 LB2102 data in SCLC/LCNEC selected for rapid oral presentation at ASCO 2026 (Abstract #8012).
- LB2102 is a dnTGFBR2-armored DLL3-targeted CAR-T with a manageable safety profile and early clinical activity in solid tumors.
- Novartis holds exclusive worldwide license for DLL3 CAR-T therapies; Legend conducts current Phase 1, Novartis handles later development/commercialization.
- CARTITUDE-4 cytogenetic subgroup analysis (Abstract #7536) shows efficacy/safety in high- and standard-risk patients responding to bridging therapy.
- CARVYKTI approved in 18 countries, treating >10,000 patients; first and only BCMA-targeted CAR-T for multiple myeloma after ≥1 prior line.
- Investor relations event at ASCO on May 31, 2026, at 6:15 p.m. CT.
Financial Impact
No financial figures disclosed. LB2102 is early-stage (Phase 1) with no revenue; CARVYKTI commercial expansion continues but no specific sales data provided.
Risk Factors
- LB2102 is early-stage (Phase 1); solid tumor CAR-T has historically low success rates.
- CARVYKTI faces competition from other BCMA-targeted therapies (e.g., Abecma, Tecvayli).
- CARVYKTI boxed warning includes CRS, neurotoxicity, secondary malignancies; safety concerns could limit adoption.
- No financial guidance or revenue figures provided in this release.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
1d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 2, 2026
12d ago
|
6-K
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $35.87 (−1.13%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $35.87 (−1.13%) |
|
Jun 1, 2026
13d ago
|
6-K
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $35.87 (+40.61%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $35.87 (+40.61%) |
|
May 21, 2026
24d ago
|
6-K
| $29.37 $29.53 | ▲ +0.54% | ▼ −0.04% | $35.87 (+22.13%) |
|
May 21, 2026
24d ago
|
Press Release
| $29.37 $29.53 | ▲ +0.54% | ▼ −0.04% | $35.87 (+22.13%) |
|
May 12, 2026
4w ago
|
6-K
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $35.87 (+26.93%) |
|
May 12, 2026
4w ago
|
Press Release
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $35.87 (+26.93%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $23.56 $22.77 | ▼ −3.35% | ▼ −3.34% | $35.87 (+52.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access